Ruta Rao, MD

Panelists provide an overview of the treatment landscape for patients with HER2-positive metastatic breast cancer.

As more drugs become available in the HER2 arena, clinicians will be faced with increasing challenges regarding which sequences and combinations of drugs will be the best for their patients. In the era in which we practice, a great deal of this is likely to be dictated by the payers.